Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Sulphate in Perinatal Asphyxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Babies eligible for the study were:~  1. Term or post term~ 2. Less than 6 hours of age and had~ 3. severe perinatal asphyxia as manifested by any three of the following criteria.~     * History of fetal distress (late deceleration, Loss of beat to beat variability, fetal bradycardia, meconium stained amniotic fluid)~    * Need for immediate neonatal ventilation with bag and mask or through endotracheal intubation for 2 minutes or more after delivery~    * A 5-minute Apgar score of \< 6~    * Base deficit 15 mEq/L in cord blood or admission arterial or cord blood pH 4.Moderate to severe encephalopathy~Exclusion Criteria:~* Patients with severe IUGR~* Any condition unrelated to asphyxia~* Maternal prenatal magnesium administration~* Metabolic disorder~* Chromosomal anomalies; and~* Congenital malformations were excluded from the study

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 6 Hours
- Healthy Volunteers: f

Study Arms:
- Magnesium sulphate, neurological outcome (Type: ACTIVE_COMPARATOR): Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth
- Placebo (Type: PLACEBO_COMPARATOR): Placebo every 24 hours for 3 doses starting from 6 hours after birth

Based on this trial design, predict the completion outcome and termination type (if applicable).